Barinthus Bio and Clywedog Therapeutics Announce Definitive Merger Agreement to Create Nasdaq-Listed Clywedog Therapeutics, Inc.

The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are bei...

October 01, 2025 | Wednesday | News
Trump Prescribes a 100% Tariff: Because Nothing Says “Affordable Healthcare” Like Doubling the Price of Pills

US President Donald Trump has announced a 100% import tariff on all branded or patented pharmaceutical products, effective 1 October. The steep duty will d...

September 28, 2025 | Sunday | Analysis
European Commission Approves Lilly’s Kisunla™ (donanemab) for Early Symptomatic Alzheimer’s Disease

Approved for use in the earliest symptomatic stages, Kisunla is the only once-monthly amyloid plaque–targeting therapy with evidence supporting tre...

September 26, 2025 | Friday | News
Swisslog Healthcare Achieves HITRUST Certification, Underscoring Commitment to Data Security and Compliance

Certification validates Swisslog Healthcare's dedication to protecting sensitive data and meeting rigorous industry standards Swisslog Healthcar...

September 26, 2025 | Friday | News
Eisai and Biogen Gain Australian Approval for LEQEMBI® in Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. announced that the Therapeutic Goods Administration (TGA) of Australia has approved LEQEMBI® (lecanemab), a humanized...

September 25, 2025 | Thursday | News
Alvotech and Fuji Pharma Secure Japanese Approval for Three New Biosimilars: Denosumab, Golimumab, and Aflibercept

Alvotech a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced th...

September 22, 2025 | Monday | News
Ipsen Secures MHLW Approval for Bylvay® in Japan to Treat Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC)

Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive familial...

September 22, 2025 | Monday | News
Ono Pharmaceutical and Deciphera Secure European Commission Approval for Vimseltinib (ROMVIMZA™) as First Therapy for TGCT in the EU

Vimseltinib is the first and only therapy with marketing authorization for the treatment of TGCT in the European Union Ono Pharmaceutical Co.,...

September 18, 2025 | Thursday | News
Belite Bio Completes Phase 3 DRAGON Trial of Tinlarebant in Stargardt Disease

Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S....

September 15, 2025 | Monday | News
AVITA Medical Secures CE Mark for RECELL® GO, Expanding European Access to Innovative Burn Care

- AVITA Medical, Inc., a leading therapeutic acute wound care company,announced it has received the CE Mark under the European Union Medical Device Regul...

September 15, 2025 | Monday | News
Zhimeng Biopharma Receives NMPA Approval to Begin Phase 2 Trial of Novel Potassium Channel Opener CB03-154 for Refractory Epilepsy

Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154...

September 12, 2025 | Friday | News
QIAGEN Secures CE-IVDR Certification for Full QIAstat-Dx Portfolio, Expands Syndromic Testing Panels

Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnosti...

September 11, 2025 | Thursday | News
InnoCare Pharma Wins Singapore HSA Approval for HIBRUKA Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that HIBRUKA ...

September 09, 2025 | Tuesday | News
NurExone Biologic Secures US Patent Allowance for Proprietary Exosome Production Process Strengthening Global Market Position

NurExone Biologic Inc. , a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that the United S...

September 09, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close